Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) and Datavault AI (NASDAQ:DVLT – Get Free Report) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.
Institutional & Insider Ownership
13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 0.7% of Datavault AI shares are owned by institutional investors. 24.2% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 7.7% of Datavault AI shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Coeptis Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, Datavault AI has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coeptis Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Datavault AI | 1 | 1 | 1 | 1 | 2.50 |
Datavault AI has a consensus price target of $2.50, suggesting a potential upside of 1,526.55%. Given Datavault AI’s stronger consensus rating and higher possible upside, analysts clearly believe Datavault AI is more favorable than Coeptis Therapeutics.
Valuation and Earnings
This table compares Coeptis Therapeutics and Datavault AI”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coeptis Therapeutics | $1.36 million | 104.44 | -$11.92 million | ($1.63) | -1.64 |
| Datavault AI | $39.09 million | 3.73 | -$78.99 million | ($0.42) | -0.37 |
Coeptis Therapeutics has higher earnings, but lower revenue than Datavault AI. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Datavault AI, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Coeptis Therapeutics and Datavault AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coeptis Therapeutics | -773.72% | -49.45% | -46.88% |
| Datavault AI | -370.21% | -46.04% | -39.35% |
Summary
Datavault AI beats Coeptis Therapeutics on 11 of the 15 factors compared between the two stocks.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
About Datavault AI
Datavault AI Inc., a data sciences technology company, owns and operates data management and supercomputer platforms. It offers data technology and software solutions. The company was formerly known as WiSA Technologies, Inc. and changed its name to Datavault AI Inc. in February 2025. Datavault AI Inc. was incorporated in 2010 and is headquartered in Beaverton, Oregon.
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
